EP Patent

EP4106724A1 — Glp-1 compositions and uses thereof

Assigned to Novo Nordisk AS · Expires 2022-12-28 · 3y expired

What this patent protects

The present invention relates to pharmaceutical compositions of the GLP-1 peptide semaglutide comprising no more than 0.1 %(w/w) phenol and above 6.4 mg/ml sodium chloride, their preparation, kits comprising such compositions as well as uses thereof.

USPTO Abstract

The present invention relates to pharmaceutical compositions of the GLP-1 peptide semaglutide comprising no more than 0.1 %(w/w) phenol and above 6.4 mg/ml sodium chloride, their preparation, kits comprising such compositions as well as uses thereof.

Drugs covered by this patent

Patent Metadata

Patent number
EP4106724A1
Jurisdiction
EP
Classification
—
Expires
2022-12-28
Drug substance claim
No
Drug product claim
No
Assignee
Novo Nordisk AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.